Rejuvenation Technologies, spearheaded by founders John Ramunas and Glenn Markov, is progressing with RTI-LNG1 for fibrotic interstitial lung disease (Non-IPF). Utilizing their innovative approach, they aim to combat the challenges of telomere attrition, a key mechanism of aging.
×
Rejuvenation Technologies � RTI-LNG1(Non IPF)
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD